Vectura Group plc Notice of Results (4580O)

TIDMVEC

RNS Number : 4580O

Vectura Group plc

09 February 2021

Notice of Preliminary Results

Chippenham, UK - 9 February 2021 : Vectura Group plc (LSE: VEC) ("Vectura" or "the Group"), an industry-leading inhalation CDMO, plans to announce its Preliminary Results for the year ended 31 December 2020 on Tuesday 9 March 2021.

Will Downie, Chief Executive Officer, and Paul Fry, Chief Financial Officer will host a live webcast and conference call for analysts at 9:30am GMT on the morning of the results.

Access to the webcast and presentation slides will be made available on Vectura's website .

- Ends-

For more information, please contact:

Vectura Group plc

   Elizabeth Knowles - VP Investor Relations                          +44 (0)7767 160 565 
   David Ginivan - VP Corporate Communications                  +44 (0)7471 352 720 
   Consilium Strategic Communications                             +44 (0)20 3709 5700

Mary-Jane Elliott / Sue Stuart / David Daley

About Vectura

Vectura is a provider of innovative inhaled drug delivery solutions that enable partners to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies.

Vectura has thirteen key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork.

For further information, please visit Vectura's website at www.vectura.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORFLFVIFFIAIIL

(END) Dow Jones Newswires

February 09, 2021 05:34 ET (10:34 GMT)

Vectura (LSE:VEC)
Historical Stock Chart
From Apr 2024 to May 2024